LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.44 2.52

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.3

Max

2.44

Belangrijke statistieken
By Trading Economics
Inkomsten	-27M -17M
Verkoop	586K 718K
EPS	-0.125
Winstmarge	-2,366.017
Werknemers	23
EBITDA	-5.5M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+123.01% upside

Dividenden
By Dow Jones
Volgende Winsten	12 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-25M 458M
Vorige openingsprijs	-0.08
Vorige sluitingsprijs	2.44

Nieuwssentiment

By Acuity

50%

148 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.275 / 0.33 Steun & Weerstand

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 mei 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mei 2026, 16:49 UTC

Winsten

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mei 2026, 16:26 UTC

Belangrijke Marktbewegers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mei 2026, 23:51 UTC

Marktinformatie

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mei 2026, 22:33 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mei 2026, 21:53 UTC

Winsten

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mei 2026, 21:02 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mei 2026, 20:55 UTC

Winsten

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mei 2026, 20:30 UTC

Populaire aandelen

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mei 2026, 20:20 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 mei 2026, 20:20 UTC

Marktinformatie

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Adj EPS 3c >BULL

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Rev $159.9M >BULL

21 mei 2026, 20:18 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mei 2026, 20:18 UTC

Winsten

Webull 1Q Loss/Shr 4c

21 mei 2026, 19:43 UTC

Marktinformatie

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mei 2026, 18:58 UTC

Winsten

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mei 2026, 18:15 UTC

Marktinformatie

Gold Higher For Second Consecutive Day -- Market Talk

21 mei 2026, 17:40 UTC

Marktinformatie

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mei 2026, 17:04 UTC

Marktinformatie

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mei 2026, 17:01 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mei 2026, 16:20 UTC

Marktinformatie

Winsten

Stellantis Targets Distant but Constructive -- Market Talk

21 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

123.01% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.33 USD 123.01%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

148 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.